Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bristol-Myers Squibb Co (BMY) vs Duolingo Inc (DUOL) Price & Performance

Bristol-Myers Squibb CoTrade
Duolingo IncTrade

Price performance (Past 24H)

Key statistics

Bristol-Myers Squibb Co vs Duolingo Inc — how do they compare? Bristol-Myers Squibb Co trades at $63.83 (market cap $129.94B), while Duolingo Inc trades at $129.36 (market cap $6.34B). The key difference: Bristol-Myers Squibb Co is far larger — about 20.5× Duolingo Inc's market cap, and Bristol-Myers Squibb Co pays a 3.96% dividend while Duolingo Inc pays none. Which is the better fit depends on your goals.

BMYDUOL
Market Cap
$129.94B$6.34B
Sector
HealthTechnology
52-Week High
$65.89$369.19
52-Week Low
$42.60$90.03
Enterprise Value
$163.92B$5.11B
Dividend Yield
3.96%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bristol-Myers Squibb Co

Bristol Myers Squibb (BMY) trades at $64.84, up 0.19% today, with a bullish technical signal from moving averages and strong fundamental health evidenced by a 14.01 P/E ratio and 18.87% net income margin. Recent earnings beats and a $2.3 billion manufacturing investment in Houston highlight operational strength, while analyst consensus is mixed with a $68.56 price target.

The outlook is positive due to earnings momentum and strategic investments, but risks include patent expirations and high debt levels. Wall Street sentiment is cautiously optimistic, with institutional buying supporting the stock's potential for moderate upside from current levels.

Duolingo Inc

Duolingo (DUOL) trades at $132.75, down 3.24% over 24 hours, with a bullish technical outlook from moving averages but neutral oscillators. The company reported strong Q2 2026 earnings, beating EPS estimates with $0.66 versus $0.604 expected, driven by 23% daily active user growth. Revenue reached $1.04 billion in 2025, with net income surging to $414 million, though Q3 2026 revenue guidance fell short of expectations, causing recent stock pressure.

The investment outlook is mixed: robust user growth and profitability metrics like a 35.87% net margin support upside, but decelerating bookings growth and margin pressures from AI investments pose risks. Analysts show cautious optimism with a $121 consensus target, highlighting the stock's sensitivity to monetization trends amid competitive threats.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Bristol-Myers Squibb Co

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.

Read more on BMY

About Duolingo Inc

Duolingo Inc is a mobile learning platform to learn languages and the top-grossing app in the Education category on both Google Play and the Apple App Store. It has three predominant sources of revenue

Read more on DUOL